Published in Nat Immunol on July 01, 2008
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol (2009) 3.84
From vaccines to memory and back. Immunity (2010) 3.30
Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One (2009) 2.93
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90
Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol (2009) 2.43
Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog (2010) 2.30
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
Naturally-Acquired Immune Response against Plasmodium vivax Rhoptry-Associated Membrane Antigen. PLoS One (2016) 2.05
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog (2010) 2.03
Advances and challenges in malaria vaccine development. J Clin Invest (2010) 2.03
Disease ecology, biodiversity, and the latitudinal gradient in income. PLoS Biol (2012) 2.00
The contribution of Plasmodium chabaudi to our understanding of malaria. Trends Parasitol (2011) 1.99
A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J (2012) 1.87
Population genetics of malaria resistance in humans. Heredity (Edinb) (2011) 1.85
Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe Plasmodium falciparum malaria. PLoS Pathog (2009) 1.81
Induction of an IL7-R(+)c-Kit(hi) myelolymphoid progenitor critically dependent on IFN-gamma signaling during acute malaria. Nat Immunol (2010) 1.80
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J (2009) 1.72
An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis (2013) 1.72
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One (2012) 1.58
CD8+ T effector memory cells protect against liver-stage malaria. J Immunol (2011) 1.55
Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol (2012) 1.51
Vector transmission regulates immune control of Plasmodium virulence. Nature (2013) 1.50
The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol (2009) 1.50
Immune mechanisms in malaria: new insights in vaccine development. Nat Med (2013) 1.40
In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun (2009) 1.39
B cell sub-types following acute malaria and associations with clinical immunity. Malar J (2016) 1.39
Effector memory Th1 CD4 T cells are maintained in a mouse model of chronic malaria. PLoS Pathog (2010) 1.39
Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease. Annu Rev Immunol (2014) 1.38
The impact of malaria parasitism: from corpuscles to communities. J Clin Invest (2009) 1.37
Induction of strain-transcending antibodies against Group A PfEMP1 surface antigens from virulent malaria parasites. PLoS Pathog (2012) 1.35
Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade. Proc Natl Acad Sci U S A (2011) 1.34
Interactions between worms and malaria: good worms or bad worms? Malar J (2011) 1.33
Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med (2013) 1.31
Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria. Proc Biol Sci (2010) 1.31
A comprehensive evaluation of rodent malaria parasite genomes and gene expression. BMC Biol (2014) 1.31
Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis (2011) 1.30
Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues. Parasite Immunol (2009) 1.30
Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis (2011) 1.28
Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS One (2008) 1.25
Mathematical models of within-host and transmission dynamics to determine effects of malaria interventions in a variety of transmission settings. Am J Trop Med Hyg (2013) 1.22
Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. PLoS Pathog (2013) 1.22
Memory B cells are a more reliable archive for historical antimalarial responses than plasma antibodies in no-longer exposed children. Proc Natl Acad Sci U S A (2012) 1.18
IFNγ/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children. PLoS Pathog (2014) 1.17
Schistosomiasis coinfection in children influences acquired immune response against Plasmodium falciparum malaria antigens. PLoS One (2010) 1.17
Quantitative analysis of immune response and erythropoiesis during rodent malarial infection. PLoS Comput Biol (2010) 1.16
Exposure-dependent control of malaria-induced inflammation in children. PLoS Pathog (2014) 1.16
Short-lived IFN-γ effector responses, but long-lived IL-10 memory responses, to malaria in an area of low malaria endemicity. PLoS Pathog (2011) 1.15
Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathog (2009) 1.15
Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnol J (2009) 1.14
CD4+ CD25+ Foxp3+ regulatory T cells, dendritic cells, and circulating cytokines in uncomplicated malaria: do different parasite species elicit similar host responses? Infect Immun (2010) 1.14
Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis (2009) 1.14
The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine (2009) 1.13
Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait. Blood (2012) 1.13
Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother (2012) 1.13
New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med (2014) 1.11
A set of ontologies to drive tools for the control of vector-borne diseases. J Biomed Inform (2010) 1.10
Plasmodium immunomics. Int J Parasitol (2010) 1.09
"Asymptomatic" Malaria: A Chronic and Debilitating Infection That Should Be Treated. PLoS Med (2016) 1.09
P. falciparum infection durations and infectiousness are shaped by antigenic variation and innate and adaptive host immunity in a mathematical model. PLoS One (2012) 1.09
Serological evidence of discrete spatial clusters of Plasmodium falciparum parasites. PLoS One (2011) 1.08
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine (2014) 1.07
A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med (2014) 1.07
Interactions between age and ITN use determine the risk of febrile malaria in children. PLoS One (2009) 1.06
Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol (2014) 1.05
Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum Vaccin Immunother (2013) 1.05
Performance of multiplex commercial kits to quantify cytokine and chemokine responses in culture supernatants from Plasmodium falciparum stimulations. PLoS One (2013) 1.04
Severe and uncomplicated falciparum malaria in children from three regions and three ethnic groups in Cameroon: prospective study. Malar J (2012) 1.04
A high force of plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in papua new guinean children. PLoS Negl Trop Dis (2013) 1.04
Increased interleukin-10 and interferon-γ levels in Plasmodium vivax malaria suggest a reciprocal regulation which is not altered by IL-10 gene promoter polymorphism. Malar J (2011) 1.03
Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cell Mol Life Sci (2014) 1.03
Development and assessment of plant-based synthetic odor baits for surveillance and control of malaria vectors. PLoS One (2014) 1.02
Loss and dysfunction of Vδ2⁺ γδ T cells are associated with clinical tolerance to malaria. Sci Transl Med (2014) 1.02
Malaria parasite diversity and transmission intensity affect development of parasitological immunity in a mathematical model. Malar J (2012) 1.01
Endemic Burkitt lymphoma is associated with strength and diversity of Plasmodium falciparum malaria stage-specific antigen antibody response. Blood (2013) 1.01
Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1. PLoS One (2011) 1.00
The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria. PLoS One (2012) 1.00
Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults. Malar J (2009) 1.00
Genetic susceptibility to systemic lupus erythematosus protects against cerebral malaria in mice. Proc Natl Acad Sci U S A (2010) 1.00
Gradual acquisition of immunity to severe malaria with increasing exposure. Proc Biol Sci (2015) 1.00
The nucleosome (histone-DNA complex) is the TLR9-specific immunostimulatory component of Plasmodium falciparum that activates DCs. PLoS One (2011) 0.99
Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg (2012) 0.99
Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites. J Infect Dis (2013) 0.99
Malaria's missing number: calculating the human component of R0 by a within-host mechanistic model of Plasmodium falciparum infection and transmission. PLoS Comput Biol (2013) 0.99
Circulating Th1-Cell-type Tfh Cells that Exhibit Impaired B Cell Help Are Preferentially Activated during Acute Malaria in Children. Cell Rep (2015) 0.98
Migration and malaria in europe. Mediterr J Hematol Infect Dis (2012) 0.97
Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity. J Immunol (2013) 0.97
The relationship of Plasmodium falciparum humeral immunity with HIV-1 immunosuppression and treatment efficacy in Zambia. Malar J (2009) 0.96
Malaria-related anaemia: a Latin American perspective. Mem Inst Oswaldo Cruz (2011) 0.95
NIAID workshop on immunity to malaria: addressing immunological challenges. Nat Immunol (2009) 0.95
A Plasmodium-encoded cytokine suppresses T-cell immunity during malaria. Proc Natl Acad Sci U S A (2012) 0.94
IL-22 Protects Against Liver Pathology and Lethality of an Experimental Blood-Stage Malaria Infection. Front Immunol (2012) 0.94
Infection and treatment immunizations for successful parasite vaccines. Trends Parasitol (2013) 0.94
Memory CD8 T cells specific for plasmodia liver-stage antigens maintain protracted protection against malaria. Front Immunol (2012) 0.94
Plasmodium falciparum Protein Microarray Antibody Profiles Correlate With Protection From Symptomatic Malaria in Kenya. J Infect Dis (2015) 0.93
Clearance of asymptomatic P. falciparum Infections Interacts with the number of clones to predict the risk of subsequent malaria in Kenyan children. PLoS One (2011) 0.93
Exposure, infection, systemic cytokine levels and antibody responses in young children concurrently exposed to schistosomiasis and malaria. Parasitology (2011) 0.93
Attenuation of virulence in an apicomplexan hemoparasite results in reduced genome diversity at the population level. BMC Genomics (2011) 0.93
Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian Amazon. Am J Trop Med Hyg (2010) 0.93
Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. Infect Immun (2009) 0.93
Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine. Malar J (2013) 0.93
Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med (2005) 13.27
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
The pathogenic basis of malaria. Nature (2002) 10.44
Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet (2008) 8.50
The decline in paediatric malaria admissions on the coast of Kenya. Malar J (2007) 7.45
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol (2002) 6.01
Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med (2004) 4.76
Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet (2009) 4.76
Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis (2005) 4.44
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet (2007) 4.23
Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet (2005) 4.22
Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res (2009) 3.99
Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet (2011) 3.78
Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med (2010) 3.78
Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun (2008) 3.51
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51
Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study. BMJ (2005) 3.34
CISH and susceptibility to infectious diseases. N Engl J Med (2010) 3.31
Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA (2007) 3.29
Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet (2004) 3.25
Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis (2005) 3.12
HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis (2009) 2.80
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Clinical features and pathogenesis of severe malaria. Trends Parasitol (2004) 2.73
Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. PLoS Negl Trop Dis (2010) 2.68
Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). Int J Epidemiol (2012) 2.64
Transient cross-reactive immune responses can orchestrate antigenic variation in malaria. Nature (2004) 2.56
Heritability of malaria in Africa. PLoS Med (2005) 2.49
Clinical algorithms for malaria diagnosis lack utility among people of different age groups. Trop Med Int Health (2005) 2.46
Malaria in Africa: progress and prospects in the decade since the Abuja Declaration. Lancet (2010) 2.41
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother (2009) 2.36
Iron deficiency and malaria among children living on the coast of Kenya. J Infect Dis (2004) 2.34
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials (2006) 2.33
IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar J (2007) 2.30
Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg (2008) 2.29
Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med (2013) 2.24
Defining childhood severe falciparum malaria for intervention studies. PLoS Med (2007) 2.22
Plasmodium falciparum variant surface antigen expression patterns during malaria. PLoS Pathog (2005) 2.13
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun (2011) 2.11
An immune basis for malaria protection by the sickle cell trait. PLoS Med (2005) 2.08
Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A (2007) 2.07
Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One (2011) 2.00
Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res (2010) 1.98
Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest (2008) 1.96
The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol (2002) 1.95
Maternal HIV infection and placental malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis (2007) 1.94
The effects of untreated bednets on malaria infection and morbidity on the Kenyan coast. Trans R Soc Trop Med Hyg (2004) 1.91
Malaria and nutritional status in children living on the coast of Kenya. Am J Clin Nutr (2004) 1.90
The role of the district hospital in child survival at the Kenyan Coast. Afr J Health Sci (1994) 1.90
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine (2005) 1.89
Chloroquine resistance before and after its withdrawal in Kenya. Malar J (2009) 1.88
Hypothetical performance of syndrome-based management of acute paediatric admissions of children aged more than 60 days in a Kenyan district hospital. Bull World Health Organ (2003) 1.87
Plasmodium falciparum var gene expression is modified by host immunity. Proc Natl Acad Sci U S A (2009) 1.86
Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun (2009) 1.79
Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol (2006) 1.78
Malaria as a cause of morbidity and mortality in children with homozygous sickle cell disease on the coast of Kenya. Clin Infect Dis (2009) 1.74
The effect of alpha+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med (2006) 1.73
The changing limits and incidence of malaria in Africa: 1939-2009. Adv Parasitol (2012) 1.72
Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum Mol Genet (2007) 1.72
Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PLoS One (2011) 1.71
Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med (2014) 1.71
Genomewide analysis of the host response to malaria in Kenyan children. J Infect Dis (2005) 1.66
Malaria and the red cell. Hematology Am Soc Hematol Educ Program (2002) 1.64
Specific receptor usage in Plasmodium falciparum cytoadherence is associated with disease outcome. PLoS One (2011) 1.62
Acute bacterial meningitis in children admitted to a rural Kenyan hospital: increasing antibiotic resistance and outcome. Pediatr Infect Dis J (2002) 1.60
Kinetics of antibody responses to Plasmodium falciparum-infected erythrocyte variant surface antigens. J Infect Dis (2003) 1.57
Neonatal measles immunity in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples. J Infect Dis (2005) 1.56
Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One (2008) 1.53
Nonimmune IgM, but not IgG binds to the surface of Plasmodium falciparum-infected erythrocytes and correlates with rosetting and severe malaria. Am J Trop Med Hyg (2002) 1.51
Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol (2012) 1.51
Positive selection of a CD36 nonsense variant in sub-Saharan Africa, but no association with severe malaria phenotypes. Hum Mol Genet (2009) 1.50
Plasmodium falciparum antigenic variation. Mapping mosaic var gene sequences onto a network of shared, highly polymorphic sequence blocks. Mol Microbiol (2008) 1.50
B cell memory to 3 Plasmodium falciparum blood-stage antigens in a malaria-endemic area. J Infect Dis (2005) 1.47
Plasmodium falciparum infections are associated with agglutinating antibodies to parasite-infected erythrocyte surface antigens among healthy Kenyan children. J Infect Dis (2002) 1.46
High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood (2010) 1.44
Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis (2005) 1.44
Evidence for over-dispersion in the distribution of clinical malaria episodes in children. PLoS One (2008) 1.44
Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS One (2011) 1.43
Protection against clinical malaria by heterologous immunoglobulin G antibodies against malaria-infected erythrocyte variant surface antigens requires interaction with asymptomatic infections. J Infect Dis (2004) 1.41
Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood (2009) 1.40
The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol (2007) 1.38
Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in Plasmodium falciparum. Mol Biol Evol (2010) 1.38
Dendritic cells, pro-inflammatory responses, and antigen presentation in a rodent malaria infection. Immunol Rev (2004) 1.36
Wind direction and proximity to larval sites determines malaria risk in Kilifi District in Kenya. Nat Commun (2012) 1.36
Excess child mortality after discharge from hospital in Kilifi, Kenya: a retrospective cohort analysis. Bull World Health Organ (2011) 1.34
Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence. Am J Trop Med Hyg (2006) 1.33
Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2. Parasite Immunol (2002) 1.32
Short report: Positive correlation between rosetting and parasitemia in Plasmodium falciparum clinical isolates. Am J Trop Med Hyg (2002) 1.31
Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. J Clin Invest (2012) 1.31
Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya. PLoS One (2010) 1.30
An increase in the burden of neonatal admissions to a rural district hospital in Kenya over 19 years. BMC Public Health (2010) 1.29
Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis (2011) 1.28
The frequency of BDCA3-positive dendritic cells is increased in the peripheral circulation of Kenyan children with severe malaria. Infect Immun (2006) 1.28
Haemoglobin C and S role in acquired immunity against Plasmodium falciparum malaria. PLoS One (2007) 1.28